通过将新型抗癌药物引入临床实践，早期乳腺癌 (eBC) 的治疗前景不断扩大。在育龄期间，患有 eBC 的女性应了解所建议的全身治疗可能导致卵巢早衰 (POI) 和不孕的潜在风险。尽管女性生育能力的话题与癌症患者越来越相关，但关于可用于 eBC 治疗的新药物的性腺毒性的信息有限。缺乏卵巢功能生物标志物的临床试验分析和前瞻性数据。本系统评价的目的是报告使用属于临床实践使用或正在开发的 eBC 管理新药物的女性生育风险的现有临床前和临床数据。本综述强调了显然需要进行额外的研究工作，以提高我们对新型抗癌药物的性腺毒性的理解。版权所有 © 2024。由 Elsevier Ltd 出版。

The therapeutic landscape for early breast cancer (eBC) has expanded by introducing novel anticancer agents into clinical practice. During their reproductive years, women with eBC should be informed of the potential risk of premature ovarian insufficiency (POI) and infertility with the proposed systemic therapy. Although the topic of female fertility is becoming increasingly relevant in patients with cancer, limited information is available on the gonadotoxicity of new agents available for eBC treatment. Analyses from clinical trials and prospective data on ovarian function biomarkers are lacking. The purpose of this systematic review is to report the available preclinical and clinical data on female fertility risk with the use of the new agents that are part of clinical practice use or under development for eBC management. This review highlights the clear need to perform additional research efforts to improve our understanding on the gonoadtoxicity of new anticancer agents.Copyright © 2024. Published by Elsevier Ltd.